ALN-CFB
RNA / oligonucleotide
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other Complement Factor B drugs
Iptacopan, HRS-5965, FWY003. Compare all 4 Complement Factor B drugs
3 other tracked programmes target this mechanism, 3 of them ahead of this one.
This drug's own stage for Paroxysmal Nocturnal Hemoglobinuria: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| ALN-CFB: this drug | Phase 1/2 | RNA / oligonucleotide | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| Eculizumab (Soliris) | Approved | Monoclonal antibody | Complement C5 | Weak signal | Featured results are safety only in this race | |
| Iptacopan (Fabhalta) | Approved | Small molecule | Complement Factor B | Partial signal | NCT04558918: At 24 weeks, without transfusion: Hb increase of 2 g/dL or more in 51 of 60 on iptacopan vs 0 of 35 on anti-C5; Hb of 12 g/dL or more in 42 of 60 vs 0 of 35. Superiority shown on both primaries. NCT04820530: Single arm, 24 weeks: estimated 92.2% (95% CI 82.5 to 100.0) of 40 complement-inhibitor-naive patients had a sustained Hb increase of 2 g/dL or more without transfusion. No comparator. | |
| Pegcetacoplan (Empaveli) | Approved | Peptide | Complement C3 | Partial signal | NCT03500549: Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP (Baseline and Week 16): Pegcetacoplan to Pegcetacoplan 2.37 Grams per deciliter (g/dL) (Standard Error 0.363) | Eculizumab to Pegcetacoplan -1.47 Grams per deciliter (g/dL) (Standard Error 0.666) | |
| Ravulizumab (Ultomiris) | Approved | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-5965 | Phase 3 | Undisclosed | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| Pozelimab (Veopoz) | Phase 3 | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| FWY003 | Phase 2(overall) | Undisclosed | Complement Factor B | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Zaltenibart | Phase 2 | Monoclonal antibody | MASP-3 | Weak signal | NCT05972967: Interim (data cut-off 8 July 2024): primary endpoints were safety and tolerability; zaltenibart was well tolerated, treatment-related adverse events in 46.2% of patients (mostly mild to moderate), 1 discontinuation for a treatment-emergent serious adverse event. Hemoglobin rose from a mean baseline of 9.26 g/dL by 3.39 g/dL at day 29 and 3.27 g/dL at day 169 on add-on to ravulizumab (N=13), and by 3.85 g/dL at day 309 on monotherapy (N=6, P=0.003). |
Compare side by side
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow ALN-CFB to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.